These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 39101180

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
    Wei HH, Lai YC, Lin G, Lin CW, Chang YC, Chang JW, Liou MJ, Chen IW.
    Diabetol Metab Syndr; 2024 Jan 23; 16(1):26. PubMed ID: 38254155
    [Abstract] [Full Text] [Related]

  • 24. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.
    McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y.
    Front Oncol; 2024 Jan 23; 14():1417175. PubMed ID: 38974234
    [Abstract] [Full Text] [Related]

  • 25. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 26. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 23; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 27. Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer.
    Sothornwit J, Phunmanee A, Pongchaiyakul C.
    Front Endocrinol (Lausanne); 2019 Mar 23; 10():352. PubMed ID: 31244772
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246400. PubMed ID: 36512357
    [Abstract] [Full Text] [Related]

  • 32. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 01; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 33. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J.
    JAMA Oncol; 2020 Jun 01; 6(6):865-871. PubMed ID: 32297899
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M, French Network of Regional Pharmacovigilance Centers.
    J Immunother Cancer; 2020 Dec 01; 8(2):. PubMed ID: 33428586
    [Abstract] [Full Text] [Related]

  • 36. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
    Okubo M, Hataya Y, Fujimoto K, Iwakura T, Matsuoka N.
    J Diabetes Investig; 2023 Jan 01; 14(1):147-150. PubMed ID: 36251515
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
    Cho YK, Jung CH.
    Diabetes Metab J; 2023 Nov 01; 47(6):757-766. PubMed ID: 37482654
    [Abstract] [Full Text] [Related]

  • 40. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.
    Liu J, Shi Y, Liu X, Zhang D, Zhang H, Chen M, Xu Y, Zhao J, Zhong W, Wang M.
    Transl Oncol; 2022 Oct 01; 24():101473. PubMed ID: 35905639
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.